MABWELL-B

2493
17.8000.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:11

Overview

MABWELL-B (2493)

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological...

Open
18.250
High
18.250
Low
17.300
Prev. Close
17.800
Volume
305.20K
Turnover
5.35M
Avg Price
17.515
Bid/Ask Ratio
-66.67%
Amplitude
5.34%
52wk High
31.460
Volume Ratio
0.76
Turnover Ratio
0.65%
52wk Low
17.040
HK Mkt Cap
838.92M
Market CapHKD
7.95B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-2.74
EPSDynamic
-2.36
EPSStatic
--
BVPS
1.87
P/B
9.53
HK Shares
47.13M
Dividend YieldTTM
--
DividendTTM
--
Shares
446.73M
Min lot size
200
Currency
HKD

MABWELL-B Analyst Rating

View more

Forecast & Rating

Aug 31, 2026
Price forecast
HK$40.99130.27%
Forecast & RatingBuy
1analysts
  • Strong buy0.00%
  • Buy100.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    2493.HK traced a high-open fade and afternoon rebound on 16 Nov: it slipped from HK$17.79 at the open to HK$17.30 at 13:55, then recovered to HK$17.65 by the close, still 0.79% below the open and within a 2.8% high-to-low range, on 286,000 shares and HK$5.00 million turnover, a thin 0.65% turnover rate. Morning volume of 107,600 shares gave way to 178,400 in the afternoon, with turnover rising from HK$1.89 million to HK$3.11 million as the price stabilised. The muted action came as the overhang from Mabwell's wider Q3 loss and lower revenue offset pipeline news: 9MW1911's Phase Ib/IIa COPD data previously showed up to an 81% reduction in exacerbations, while 9MW2821's Phase II trial in ADC-pretreated triple-negative breast cancer showed a 30% objective response rate. Those catalysts have not yet translated into sustained participation. At HK$17.65, the stock sits near the upper half of the day's HK$17.30-HK$17.79 range but below the morning high; market capitalisation is HK$7.95 billion, PB 9.53x and PE -6.5x. Though the clinical readouts remain relevant, the wider Q3 loss and lower revenue, together with the 0.65% turnover, still cap the rebound.

  2. Nov, 5

    Mabwell-B opened roughly 7% lower at HK$17.21 and recovered quickly, touching a morning-session high of HK$18.98 at 10:58 BJ before drifting between HK$18.26 and HK$18.59 in the afternoon and closing at HK$18.54, essentially flat against the prior close on thin volume of 275,000 shares and a 0.58% turnover rate, as the market kept digesting a wider third-quarter loss. Q3 revenue fell 28.94% year on year to HK$361 million while the net loss expanded 261.97% to HK$183 million; for the first nine months revenue reached RMB621 million, up 9.77%, with the loss widening to RMB678 million. Oral-report data on 9MW2821 at ESMO 2026, showing a 30% objective response rate in triple-negative breast cancer, offered partial support. The stock is down 33.31% year to date, 41.07% below its 29 April high of HK$31.46 and still 8.8% above its 28 October low of HK$17.04, but remains under both MA20 (HK$19.06) and MA60 (HK$20.51), though an approaching cornerstone lock-up expiry keeps potential supply in view.

  3. Oct, 22

    Mabwell-B faded from an early spike, opening flat at HK$19.48, drifting lower through the morning and touching HK$18.63 late in the afternoon before closing at HK$19.05, down 0.99% from the prior HK$19.24 close on thin turnover of just 137,000 shares (HK$2.6 million, 0.43% turnover rate), with a lack of follow-through buying the main drag. Clinical headlines were constructive - 9MW2821 posted a 30% objective response rate in Phase II ADC-pretreated triple-negative breast cancer and won an oral slot at the 2026 ESMO Congress, while the Nectin-4 ADC has three of four China Phase III trials enrolling - yet they did not offset the thin liquidity. Q2 2026 revenue of HK$214 million rose 246% year on year, but the net loss still reached HK$323 million with a -151% net margin and EPS of -HK$0.75, leaving the profit inflection unproven. The stock is down 31.5% year to date, 39.5% below its post-listing 52-week high of HK$31.46 set in April, only 5.8% above the HK$18 low of 14 October, and sits below its MA20 of 20.16 and MA60 of 21.04. Though the spin-off of the TCE pipeline into Lianwei Chuangyuan, paired with a RMB 825 million capital increase and RMB 826 million equity transfer, may ease future pipeline funding.

  4. Oct, 15

    Mabwell-B traded in a narrow, thin range, opening at HK$19.48, slipping to HK$18.85 in the morning session and recovering to HK$19.17 in the afternoon before closing at HK$19.09, down about 1.6% from the prior close of HK$19.40 on just 78,400 shares and roughly HK$1.49 million turnover, a 0.24% turnover rate. The price sits below its MA20 of HK$20.53 and MA60 of HK$21.23, down 31.3% year-to-date and 39.3% below its 52-week high of HK$31.46 set in April, though still 6% above the 52-week low of HK$18.00 touched yesterday. Q2 2026 revenue reached HK$213.7 million, up 246% year-on-year, while the net loss widened 13.6% to HK$323.1 million, leaving PE at -7.88 and PB at 8.48. Clinical news flow continued: 9MW1911's COPD data at ERS 2026 showed up to an 81% reduction in exacerbations, and the Nectin-4 ADC 9MW2821 has entered four Phase III trials. Still, the revenue ramp has yet to close the loss, and the stock remains under its moving averages.

  5. Oct, 13

    Mabwell-B slid in a one-way retreat today, opening at HK$20.58 which also marked the session high, then dropping to an intraday low of HK$18.35 at 15:24 BJ before closing at HK$19.29, down 5.44% from the prior HK$20.40 close, on HK$8.94 million turnover. The pullback came even as H1 FY26 revenue more than doubled to RMB312.45 million and the net loss narrowed 5.08% to RMB524.2 million; the anti-ST2 antibody 9MW1911 cut COPD exacerbations by up to 81%, and Brazil ANVISA cleared GMP inspection for its denosumab injections. Still, Q2 alone showed a HK$323.1 million net loss and a -151.19% net margin, so revenue growth has not yet closed the loss. The shares are down 30.61% year-to-date, 38.68% below the 52-week high of HK$31.46 set on April 29, and sit under both the MA20 of 20.665 and MA60 of 21.357. Though HK$18.35 is already within 5.12% of the 52-week low.

News